By Colin Kellaher


Yumanity Therapeutics Inc. on Wednesday said the U.S. Food and Drug Administration has placed a partial clinical hold on multidose clinical trials of YTX-7739, its most advanced product candidate, in the progressive nervous-system disorder Parkinson's disease.

The Boston clinical-stage biopharmaceutical company said the FDA agency hasn't halted all clinical programming, and that it is permitting a planned single-dose clinical trial to proceed.

Yumanity said it received an email notification of the partial hold from the FDA, adding that it expects to receive more details from the agency within 30 days.

The company said the partial hold suspends initiation of multiple-dose clinical trials in the U.S. until it has addressed the FDA's questions.


Write to Colin Kellaher at


(END) Dow Jones Newswires

January 19, 2022 08:02 ET (13:02 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.